Phase 3Completed

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. (V-Mono)

A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono)

Sponsor
Novartis Pharmaceuticals (Industry)
Enrollment
350 enrolled
Conditions
Hypercholesterolemia
Interventions
Inclisiran; Ezetimibe; Matching Placebo for Inclisiran; Matching Placebo for Ezetimibe
Ages
adults, older adults
Registry
NCT05763875

Full record on ClinicalTrials.gov

From the registry

CKJX839D12304 was a research study to determine if the study treatment, called inclisiran, in comparison to placebo and ezetimibe effectively reduces Low-Density Lipoprotein Cholesterol (LDL-C) as measured by percentage change from baseline to Day 150. This study was conducted in eligible participants with primary hypercholesterolemia not receiving any lipid-lowering therapy (LLT), with a 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk of less than 7.5%.

Primary outcomes

  • Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered